Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: Effects of bariatric surgery vs standard medical therapy

International Journal of Obesity

Volumn 38, Issue 3, 2014, Pages 364-370

  Malin, S K ^a,b   Samat, A ^a   Wolski, K ^a   Abood, B ^a   Pothier, C E ^a   Bhatt, D L ^c   Nissen, S ^a   Brethauer, S A ^a   Schauer, P R ^a   Kirwan, J P ^a,b   Kashyap, S R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

bariatric surgery; diabetes; gastrointestinal hormones; glycemic control; insulin resistance; insulin secretion

Indexed keywords

ACYLATED GHRELIN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN SENSITIZING AGENT; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY COMPOSITION; BODY FAT; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; POSTOPERATIVE PERIOD; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; TEST MEAL; ACYLATION; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; METABOLISM; OBESITY, MORBID; PHOTON ABSORPTIOMETRY; PROSPECTIVE STUDY; SECRETION (PROCESS); STOMACH BYPASS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ABSORPTIOMETRY, PHOTON; ACYLATION; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; FOOD HABITS; GASTRIC BYPASS; GHRELIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY, MORBID; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84896315912     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.196     Document Type: Article

References (43)

1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846
2. Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR et al. Exercise and type 2 diabetes: The American College of Sports Medicine and the American Diabetes Association: Joint position statement executive summary. Diabetes Care 2010; 33: 2692-2696
3. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obesity Surg 2009; 19: 1605-1611
4. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-1585
5. Schauer PR, Kashyap SR, Wolski K, Brethauer S, Kirwan JP, Pothier CE et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-1576
6. Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel Courtin C, Gass M et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: A randomized, prospective trial. Obesity Surg 2012; 22: 740-748
7. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: A prospective, double blind study. Ann Surg 2008; 247: 401-407
8. Mingrone G, Nolfe G, Gissey GC, Iaconelli A, Leccesi L, Guidone C et al. Circadian rhythms of GIP and GLP1 in glucose-Tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia 2009; 52: 873-881
9. Cummings DE, Overduin J, Foster Schubert KE. Gastric bypass for obesity: Mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89: 2608-2615
10. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obesity Relat Dis 2007; 3: 597-601
11. Kashyap SR, Daud S, Kelly KR, Gastaldelli A, Win H, Brethauer S et al. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes 2010; 34: 462-471
12. Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009; 150: 2518-2525
13. Davies JS, Kotokorpi P, Eccles SR, Barnes SK, Tokarczuk PF, Allen SK et al. Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Mol Endocrinol 2009; 23: 914-924
14. Theander Carrillo C, Wiedmer P, Cettour Rose P, Nogueiras R, Perez Tilve D Pfluger P et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006; 116: 1983-1993
15. Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings De et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010; 59: 2145-2151
16. Cummings DE, Weigle D, Frayo RS, Breen P, Ma M, Dellinger EP et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630
17. Kashyap SR, Bhatt DL, Wolski K, Wantanabe RM, Abdul-Ghani MA, Abood B et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: Analysis of a randomized control trial comparing surgery vs. intensive medical treatment. Diabetes Care 2013; 36: 2175-2182
18. Patel RT, Shukla AP, Ahn SM, Moreira M, Rubino F. Surgical control of obesity and diabetes: The role of intestinal vs gastric mechanisms in the regulation of body weight and glucose homeostasis. Obesity 2013; e-pub ahead of print 20 March 2013; doi:10.1002/oby.20441
19. Kashyap SR, Bhatt DL, Schauer PR. Bariatric surgery vs. advanced practice medical management in the treatment of type 2 diabetes mellitus: Rationale and design of the Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently trial (STAMPEDE). Diabetes Obes Metab 2010; 12: 452-454
20. Blatnik M, Soderstrom CI. A practical guide for the stabilization of acylghrelin in human blood collections. Clin Endocrinol (Oxf) 2011; 74: 325-331
21. Falken Y, Hellstrom PM, Holst JJ, Naslund E. Changes in glucose homeostasis after Roux-en Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: Role of gut peptides. J Clin Endocrinol Metab 2011; 96: 2227-2235
22. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez J, Gutierrez C et al. Resistin adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obes Res 2004; 12: 962-971
23. Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90: 359-365
24. Engstorm BE, Ohrvall M, Sundbom M, Lind L, Karlsson FA. Meal suppression of circulating ghrelin is normalized in obese individuals following gastric bypass surgery. Int J Obes 2007; 31: 476-480
25. Rodieux F, Giusti V, D?Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastricbanding on glucose kinetics and gut hormone release. Obesity 2008; 16: 298-305
26. Samat A, Malin SK, Huang H, Schauer PR, Kirwan JP, Kashyap SR. Ghrelin suppression is associated with weight loss and insulin action following gastric bypass surgery at 12 months inobese adults with type 2 diabetes. Diabetes Obes Metab 2013; 15: 963-966
27. Barazzoni R, Zanetti M, Nagliati C, Cattin MR, Ferreira C, Giuricin M et al. Gastric bypass does not normalize obesity-related changes in ghrelin profile and leads to higher acylated ghrelin fraction. Obesity 2013; 21: 718-722
28. Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD. Changes in postprandial gut hormones after metabolic surgery: A comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2011; 7: 683-690
29. Tsubone T, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Ghrelin regulates adiposity in white adipose tissue and UCP1 mRNA expression in brown adipose tissue in mice. Regul Pept 2005; 130: 97-103
30. Yu BL, Zhao SP, Hu JR. Cholesterol imbalance in adipocytes: A possible mechanism of adipocytes dysfunction in obesity. Obes Rev 2010; 11: 560-567
31. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-4758
32. Sondergaard E, Gormsen LC, Nellemann B, Vestergaard ET, Christiansen JS Nielsen S. Visceral fat mass is a strong predictor of circulating ghrelin levels in premenopausal women. Euro J Endocrinol 2009; 160: 375-379
33. Jimenez A, Casamitjana R, Viaplana Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes mellitus after gastric bypass surgery. Diabetes Care 2013; 36: 2062-2069
34. Hagemann D, Holst JJ, Gethmann A, Banasch M, Schmidt W, Meier JJ. Glucagonlike peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regul Pept 2007; 143: 64-68
35. Chelikani P, Haver A, Reidelberger R. Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY(3-36) on food intake and gastric emptying in rats. Diabetes 2006; 55: 3038-3046
36. Damdindorj B, Dezaki K, Kurashina T, Sone H, Rita R, Kakei M et al. Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet beta-cells. FEBS Lett 2012; 586: 2555-2562
37. Bohdjalian A, Langer FB, Shakeri Leidenmuhler S, Gfrerer L, Ludvik B, Zacherl J et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg 2010; 20: 535-540
38. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308: 2489-2496
39. Balducci S, Zanuso S, Nicolucci A, De Feo P, Cavallo S, Cardelli P et al. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: A randomized controlled trial: The Italian Diabetes and Exercise Study (IDES). Arch Intern Med 2010; 170: 1794-1803
40. Malin SK, Gerber R, Chipkin SR, Braun B. Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care 2012; 35: 1-6
41. Solomon TPJ, Malin SK, Karstoft K, Haus JM, Kirwan JP. Hyperglycemia blunts the therapeutic effect of exercise on glycemic control in type 2 diabetes. JAMA 2013; 173: 1834-1836
42. Dirksen C, Jorgensen NB, Bojsen Moller KN, Jacobsen SH, Hansen DL, Worm D et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 2012; 55: 1890-1901
43. Hagobian TA, Braun B. Physical activity and hormonal regulation of appetite: Sex differences and weight control. Exerc Sport Sci Rev 2010; 38: 25-30